XV Konferencja Naukowa Polskiego Towarzystwa Hepatologicznego
Current issue
Archival Issues
Manuscript Submission
Journal Abstract
HCV Genotype 1 infection – the possibilities of individualization the therapy of interferon alpha 2a with ribavirin
Krzysztof Simon
Medical Science Review - Hepatologia 2011; 11 52-56
aaICID: 970948
Article type: Review article
IC™ Value: 3.40
Abstract provided by Publisher
Many studies have demonstrated that clinical manifestation and the outcome of
HCV infection are negatively influenced by a variety of cofactors and comorbidities. Currently
only available and accepted therapy for chronic HCV infection is combination therapy with
pegylated interferon-alpha2 (PEG-IFN) and ribavirine(RBV), which produces an overall cure
rate of approximately 50–60%. A lot of cofactors often influenced the chance of achieving a
sustained virological response (SVR). Dose modification of both currently licensed drugs for
treatment of HCV infection and variations of treatment duration are the most discussed strategies
to optimized the therapy, particulary in patients infected by genotype 1 HCV. Tailoring the
duration of peginterferon/ribavirine therapy to HCV kinetics is useful to optimize the results
of therapy. Moreover some published meta-analysis suggest that therapy with peginterferon
alpha-2a/RBV is associated with higher SVR than therapy with peginterferon alpha-2b/RBV.

ICID 970948

DOI 10.5604/17305039.970948

Related articles
  • in IndexCopernicus™
         genotyp 1 HCV [0 related records]
         pegylowany interferon alfa2a [0 related records]
         Liver Cirrhosis [321 related records]
         chronic hepatitis [19 related records]
         HCV infection [11 related records]


    Copyright © Medical Science Review - Hepatologia  2019
    Page created by Index Copernicus Ltd. All Rights reserved.